Immunotherapy In Gu Cancers News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Immunotherapy in gu cancers. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Immunotherapy In Gu Cancers Today - Breaking & Trending Today

Lenvatinib/Pembrolizumab Maintained Beneficial Outcomes When Evaluated by Tumor Size in RCC

Lenvatinib/pembrolizumab demonstrated efficacy irrespective of tumor burden in advanced renal cell carcinoma in the overall patient population of the phase 3 CLEAR study. ....

United States , Lenvatinib Lenvima , University Hospital Essen , Interdisciplinary Genitourinary Oncology , Subgroup Analysis , Western Europe , North America , Immunotherapy In Gu Cancers , Genitourinary Cancers , Immuno Oncology ,

Individualized Approach Best Informs Choice of Frontline Immunotherapy or Targeted Therapy Combinations Across RCC Histologies

Benjamin Garmezy, MD, discusses challenges associated with navigating the current frontline armamentarium in both clear cell and variant RCC, the impact of frontline IO doublets and IO/TKI regimens on patient outcomes, and the importance of ongoing combination studies for patients with variant RCC. ....

United States , Benjamin Garmezy , Genitourinary Research , Sarah Cannon Research Institute , Tennessee Oncology , Institutional Perspectives , Sarah Cannon Research Institute At Tennessee Oncology , Onclive Tv , Immunotherapy In Gu Cancers , Gu Cancers ,

Nephrectomy Offers Potential PFS Benefit in mRCC Who Underwent Immune-Targeted Therapy

Nephrectomy was associated with a progression-free survival (PFS) benefit compared with immunotherapy alone in patients with metastatic renal cell carcinoma who received immunotherapy. ....

First Affiliated Hospital Of Nanchang University , Rcc Database Consortium , First Affiliated Hospital , Nanchang University , Jiangxi Cancer Hospital , Jiangxi Provincial People , Immunotherapy In Gu Cancers , Immuno Oncology , Genitourinary Cancers , Gu Cancer , Metastatic Renal Cell Carcinoma , Bmc Cancer ,

Updated Data Continue to Aid IO-Based Frontline Treatment Decisions in Advanced RCC

Tian Zhang, MD, MHS, details how updated data presented at the 2023 ASCO Annual Meeting from trials such as KEYNOTE-426 and CLEAR have showed the sustained efficacy of VEGF plus immunotherapy combinations vs sunitinib in the first-line setting; discusses where the immunotherapy-only combination of ipilimumab and nivolumab fits in the frontline setting; and highlights how data from CONTACT-03 provided key insights on the use of immunotherapy in patients with advanced renal cell carcinoma after progression on a prior immune checkpoint inhibitor. ....

United States , Raquibul Hannan , Department Of Internal Medicine , Tian Zhang , Science Summit , Hans Hammers , Internal Medicine , Comprehensive Cancer Center , Immunotherapy In Gu Cancers , Genitourinary Cancers , Immuno Oncology ,

Enfortumab Vedotin Plus Pembrolizumab Generates Survival Benefit in Previously Untreated Advanced Urothelial Cancer

Treatment with the combination of enfortumab Vedotin and pembrolizumab led to an improvement in overall survival and progression-free survival compared with chemotherapy in previously untreated patients with locally advanced or metastatic urothelial cancer who were eligible for cisplatin- or carboplatin-containing chemotherapy. ....

City Of , United Kingdom , Thomas Powles , Eliav Barr , Barts Cancer Center , Queen Mary University Of London , Merck Research Laboratories , Queen Mary University , Immunotherapy In Gu Cancers , Urothelial Cancer , Immuno Oncology , Enfortumab Vedotin , Keynote A39 Ev 302 Trial ,